An Evidence-based Physical Therapy Prescription for Adults With X-linked Hypophosphatemia

被引:3
|
作者
Kanamalla, Karthik [1 ]
Fuchs, Rebekah [2 ]
Herzog, Casey [2 ]
Steigbigel, Keith D. [1 ]
Macica, Carolyn M. [1 ]
机构
[1] Quinnipiac Univ, Frank H Netter MD Sch Med, Dept Med Sci, North Haven, CT 06518 USA
[2] Quinnipiac Univ, Sch Hlth Sci, Dept Phys Therapy, North Haven, CT 06518 USA
关键词
X-linked hypophosphatemia; osteoarthritis; enthesopathy; functional range of motion; activities of daily living; prescription PT program; PERFORMANCE; BALANCE;
D O I
10.1210/jendso/bvac094
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: X-linked hypophosphatemia (XLH) is a rare and progressive metabolic phosphate-wasting disorder characterized by lifelong musculoskeletal comorbidities. Despite considerable physical disability, there are currently no disease-specific physical therapy (PT) recommendations for XLH designed to improve engagement and confidence in performing activities of daily living (ADL). Objective: The objective of this patient-centered study was to develop an evidence-based PT program to address gaps in the management of adult XLH without imposing unintended harm. Methods: Creation of the program was informed by a prior controlled clinical study to evaluate the physical and functional effect of XLH on adulthood, and guided by the physical presentation of participants, subjective data and patient goals acquired at intake, and by performance on multiple active range of motion (ROM) movements from the standing position. A weekly standardized interview process was used to assess progression of physical and functional abilities, gains and concerns, and to obtain timely feedback to inform future exercise modifications. Outcomes were evaluated using validated functional tools and subjective data obtained throughout the study. Results: A remote 12-week PT program was created based on collected data. Open and closed kinetic-chain exercises were developed and implemented. Functional improvements were documented, and weekly surveys indicated improved abilities and confidence to engage in ADL. Minimal improvements were observed in active upper and lower extremity ROM, reflective of substantial bony restrictions characteristic of XLH. Conclusion: This study represents the first disease-specific PT recommendations for XLH to mitigate the unique physical challenges of the adult disorder that can be modified to adapt to the current progression status of the adult disorder.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium
    Laurent, Michael R.
    Schepper, Jean De
    Trouet, Dominique
    Godefroid, Nathalie
    Boros, Emese
    Heinrichs, Claudine
    Bravenboer, Bert
    Velkeniers, Brigitte
    Lammens, Johan
    Harvengt, Pol
    Cavalier, Etienne
    Kaux, Jean-Francois
    Lombet, Jacques
    Waele, Kathleen De
    Verroken, Charlotte
    van Hoeck, Koenraad
    Mortier, Geert R.
    Levtchenko, Elena
    Walle, Johan Vande
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [42] Disease Manifestations and Complications in Dutch X-Linked Hypophosphatemia Patients
    A. Bosman
    N. M. Appelman-Dijkstra
    A. M. Boot
    M. H. de Borst
    A. C. van de Ven
    R. T. de Jongh
    A. Bökenkamp
    J. P. van den Bergh
    B. C. J. van der Eerden
    M. C. Zillikens
    Calcified Tissue International, 2024, 114 : 255 - 266
  • [43] Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease
    Balani, Shanthi
    Perwad, Farzana
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2020, 29 (05) : 531 - 536
  • [44] Effect of dipyridamole on serum and urinary phosphate in X-linked hypophosphatemia
    Seikaly, RG
    Quigley, R
    Baum, M
    PEDIATRIC NEPHROLOGY, 2000, 15 (1-2) : 57 - 59
  • [45] Increased prevalence of overweight and obesity in children with X-linked hypophosphatemia
    Zhukouskaya, Volha V.
    Rothenbuhler, Anya
    Colao, Annamaria
    Di Somma, Carolina
    Kamenicky, Peter
    Trabado, Severine
    Prie, Dominique
    Audrain, Christelle
    Barosi, Anna
    Kyheng, Christele
    Lambert, Anne-Sophie
    Linglart, Agnes
    ENDOCRINE CONNECTIONS, 2020, 9 (02) : 144 - 153
  • [46] Identification of Rare and Novel PHEX Variants in X-linked Hypophosphatemia
    Ma, Xiaosen
    Pang, Qianqian
    Gong, Yiyi
    Li, Xiang
    Liu, Wei
    Jiang, Yan
    Wang, Ou
    Li, Mei
    Xing, Xiaoping
    Xia, Weibo
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (12) : 3176 - 3185
  • [47] Iron and fibroblast growth factor 23 in X-linked hypophosphatemia
    Imel, Erik A.
    Gray, Arnie K.
    Padgett, Leah R.
    Econs, Michael J.
    BONE, 2014, 60 : 87 - 92
  • [48] Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
    Ward, Leanne M.
    Glorieux, Francis H.
    Whyte, Michael P.
    Munns, Craig F.
    Portale, Anthony A.
    Hoegler, Wolfgang
    Simmons, Jill H.
    Gottesman, Gary S.
    Padidela, Raja
    Namba, Noriyuki
    Cheong, Hae Il
    Nilsson, Ola
    Mao, Meng
    Chen, Angel
    Skrinar, Alison
    Roberts, Mary Scott
    Imel, Erik A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (08) : E3241 - E3253
  • [49] Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review
    Dodamani, Manjunath Havalappa
    Kumar, Samantha Cheryl
    Bhattacharjee, Samiksha
    Barnabas, Rohit
    Kumar, Sandeep
    Lila, Anurag Ranjan
    Memon, Saba Samad
    Karlekar, Manjiri
    Bandgar, Tushar R.
    Bandgar, Tushar R.
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2024, 68
  • [50] Cardiovascular health in pediatric patients with X-linked hypophosphatemia under two years of burosumab therapy
    Brener, Avivit
    Cleper, Roxana
    Baruch, Guy
    Rothschild, Ehud
    Yackobovitch-Gavan, Michal
    Beer, Gil
    Zeitlin, Leonid
    Kapusta, Livia
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15